RxDoctor Payments Data

William Sim, MD

Internal Medicine · Anaheim, CANPI 1437256906

Payments from drug & device makers

$9,650in general payments, 2019–2025

Across 468 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • GSK$936
  • AstraZeneca$735
  • Boehringer Ingelheim$518
  • Novo Nordisk$492
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$9,643100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)71$1,472
Lilly USA, LLC54$1,055
GSK40$936
AstraZeneca41$735
Boehringer Ingelheim21$518
Novo Nordisk25$492
Merck26$467
Pfizer20$416
Bayer15$313
Amarin Pharma, Inc.13$300
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$271
Otsuka America Pharmaceutical, Inc.12$261
Novartis12$230
Phathom Pharmaceuticals, Inc.6$153
Amgen5$136
Biohaven Pharmaceuticals, Inc.6$114
Ardelyx, Inc.4$99
Scilex Pharmaceuticals Inc.4$89
Xeris Pharmaceuticals, Inc.4$83
Biohaven Pharmaceutical Holding Company Ltd.3$79
Ironwood Pharmaceuticals, Inc4$73
Dexcom, Inc.3$69
Esperion Therapeutics, Inc.3$69
Almatica Pharma LLC4$69
Johnson & Johnson5$68
Boston Scientific2$56
Teva Pharmaceuticals USA, Inc.3$55
Sumitomo Pharma America, Inc.2$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$52
Supernus Pharmaceuticals, Inc.3$47
Shire North American Group Inc2$47
E.r. Squibb & Sons, L.L.C.2$46
Astellas Pharma US Inc2$45
Takeda Pharmaceuticals U.S.A., Inc.2$43
Eisai Inc.2$41
Radius Health, Inc.2$40
Mylan Specialty L.p.2$39
Sanofi-aventis U.S. LLC2$38
Axsome Therapeutics, Inc.2$37
Gilead2$37
Shield Therapeutics Inc2$37
Averitas Pharma Inc.1$35
Echosens North America, Inc.1$32
Optinose US, Inc.2$29
Ascensia Diabetes Care US Inc.1$26
Aimmune Therapeutics, Inc.1$25
Abbott1$24
Myriad Genetic Laboratories, Inc.1$24
Medicure Pharma Inc.1$20
Smith+Nephew1$19
Azurity Pharmaceuticals, Inc.1$18
IBSA Pharma Inc.1$17
Exact Sciences1$16
Idorsia Pharmaceuticals US Inc1$16
Dermira, Inc.1$16
Currax Pharmaceuticals LLC1$15
Otsuka Pharmaceutical Development & Commercialization, Inc.1$15
Sunovion Pharmaceuticals Inc.1$14
Kyowa Kirin, Inc.1$13

How this compares

$9,650 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$539,132
Medicare patients
787
Services billed
5,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide768$439,941
EliquisApixaban453$343,990
OzempicSemaglutide235$232,240
CreonLipase/Protease/Amylase202$227,563
JanuviaSitagliptin Phosphate304$203,131
JardianceEmpagliflozin217$156,929
RestasisCyclosporine233$156,412
TradjentaLinagliptin171$86,056
Tolvaptan26$76,446
FarxigaDapagliflozin Propanediol80$65,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$64,240
ProliaDenosumab35$59,628
VascepaIcosapent Ethyl231$58,611
Memantine Hcl ErMemantine Hcl472$50,313
EntrestoSacubitril/Valsartan71$49,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Restasis$1,472$823,9161,203 claims
PfizerEliquis$416$343,990453 claims
Boehringer IngelheimJardiance, Tradjenta$518$242,985388 claims
Novo NordiskOzempic$492$232,240235 claims
MerckJanuvia, Janumet$467$224,907343 claims
AstraZenecaFarxiga, Brilinta$735$77,34998 claims
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$15$76,44626 claims
Lilly USA, LLCMounjaro, Trulicity$1,055$67,20656 claims
GSKTrelegy Ellipta$936$64,24082 claims
AmgenProlia$136$59,62835 claims
NovartisEntresto$230$49,51271 claims
Astellas Pharma US IncMyrbetriq$45$49,238101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →